コンテンツへスキップ
Merck
  • Topical administration of tranexamic acid in primary total hip and total knee arthroplasty.

Topical administration of tranexamic acid in primary total hip and total knee arthroplasty.

The Journal of arthroplasty (2013-11-19)
Joseph G Martin, Kevin B Cassatt, Katie A Kincaid-Cinnamon, Denise S Westendorf, Ann S Garton, Jon H Lemke
要旨

Major blood loss is a known potential complication in total hip and total knee arthroplasty. We conducted a prospective, stratified, randomized, double-blind, placebo-controlled trial that evaluated 100 patients undergoing total knee or total hip arthroplasty to evaluate the effect on blood loss using the topical application of tranexamic acid. Participants received either 2 g of topical tranexamic acid or the equivalent volume of placebo into the joint prior to surgical closure. Tranexamic acid resulted in a lower mean maximum decline in postoperative hemoglobin levels when compared to placebo (P = 0.013). Patients in the tranexamic acid group demonstrated an improved but non-significant reduction in the units of blood transfused compared to placebo (P = 0.423). There was no clinically significant increase in complications in the tranexamic acid group, including no incidence of venous thromboembolism.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
trans-4-(アミノメチル)シクロヘキサンカルボン酸, 97%
USP
トラネキサム酸, United States Pharmacopeia (USP) Reference Standard
トラネキサム酸, European Pharmacopoeia (EP) Reference Standard